21 August 2021: Clinical Research
Sevoflurane-Remifentanil Versus Propofol-Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease – A Prospective Study Between 2016 and 2017 at a Single Center
Zhongliang Dai 1ACDE , Miao Lin 1BDE , Yali Li 1BE , Wenli Gao 1BDE , Ping Wang 1BDE , Juan Lin 1CE , Zhenzhen Wan 2AE* , Yuanxu Jiang 1CE*DOI: 10.12659/MSM.929835
Med Sci Monit 2021; 27:e929835
Table 4 Postoperative clinical course of 30 days.
| Variables | Sevoflurane (n=81) | Propofol (n=83) | P |
|---|---|---|---|
| Death, n (%) | 4 (5.0) | 3 (3.6) | 0.781 |
| NYHA, n (%) | |||
| I | 25 (30.9) | 24 (28.9) | 0.722 |
| II | 50 (61.7) | 48 (57.8) | 0.819 |
| III | 17 (21.0) | 18 (21.7) | 0.863 |
| IV | 9 (11.1) | 9 (10.8) | 0.926 |
| Acute myocardial infarction, n (%) | 0 | 0 | --- |
| Arrhythmias requiring treatment, n (%) | 5 (6.2) | 6 (7.2) | 0.832 |
| Cardiac dysfunction, n (%) | 2 (2.5) | 2 (2.4) | 0.956 |
| Readmission, n (%) | 8 (9.9) | 7 (8.4) | 0.682 |
| NYHA – New York Heart Association. | |||